{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T19:26:30Z","timestamp":1773948390248,"version":"3.50.1"},"reference-count":60,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T00:00:00Z","timestamp":1723680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Dapsone (DP) is employed in the management of various skin conditions, including autoimmune bullous diseases to non-enzymes (n-eAIBDs). This study aimed to assess the advantages and safety profile of DP treatment in n-eAIBDs patients. The evaluation focused on clinical remission, reduction in glucocorticosteroid (GCS) usage, and adverse incidents during a 12-month observation in a dermatology department at a Central European university. Materials and Methods: Our retrospective study included forty-one patients who met the inclusion criteria, comprising nineteen with pemphigus vulgaris, nine with pemphigus foliaceus, four with bullous pemphigoid, and nine with mucous membrane pemphigoid, including one patient with Brunsting\u2013Perry pemphigoid. Patients received 25\u201350 mg\/day of DP along with oral GCSs for a year, with a subsequent dose reduction where feasible. Results: The mean decreases in prednisone-equivalent dosages across all groups after 2, 6, and 12 months of DP treatment were 45.66%, 65.77%, and 63.03%, respectively. Throughout the 12-month observation period, 21.62% of patients experienced a relapse, while the remaining patients attained either complete or partial remission with minimal therapy. Adverse incidents were observed in 29.27% of patients; these were mild or moderate, and no severe negative effects were observed. Conclusions: DP is an effective and affordable choice to support the treatment of n-eAIBDs, but it may not be sufficient for long-term management in certain patients with severe n-eAIBDs.<\/jats:p>","DOI":"10.3390\/medicina60081324","type":"journal-article","created":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T09:29:41Z","timestamp":1723714181000},"page":"1324","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Dapsone as a Current Option for the Treatment of Autoimmune Bullous Diseases with Autoimmunity to Non-Enzymes: A Retrospective Study from a Single Central European Referral Center"],"prefix":"10.3390","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4373-6862","authenticated-orcid":false,"given":"Maciej Marek","family":"Spa\u0142ek","sequence":"first","affiliation":[{"name":"Autoimmune Blistering Dermatoses Section, Department of Dermatology, Poznan University of Medical Sciences, 60-355 Poznan, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8191-7475","authenticated-orcid":false,"given":"Magdalena","family":"Ja\u0142owska","sequence":"additional","affiliation":[{"name":"Autoimmune Blistering Dermatoses Section, Department of Dermatology, Poznan University of Medical Sciences, 60-355 Poznan, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Welc","sequence":"additional","affiliation":[{"name":"Autoimmune Blistering Dermatoses Section, Department of Dermatology, Poznan University of Medical Sciences, 60-355 Poznan, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8221-7622","authenticated-orcid":false,"given":"Monika","family":"Bowszyc-Dmochowska","sequence":"additional","affiliation":[{"name":"Cutaneous Histopathology and Immunopathology Section, Department of Dermatology, Poznan University of Medical Sciences, 60-355 Poznan, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4819-2051","authenticated-orcid":false,"given":"Marian","family":"Dmochowski","sequence":"additional","affiliation":[{"name":"Autoimmune Blistering Dermatoses Section, Department of Dermatology, Poznan University of Medical Sciences, 60-355 Poznan, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,15]]},"reference":[{"key":"ref_1","first-page":"1077","article-title":"Diagnosis of autoimmune bullous diseases","volume":"16","author":"Zillikens","year":"2018","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e15032","DOI":"10.1111\/dth.15032","article-title":"Therapeutic approaches and targets for treatment of autoimmune bullous diseases","volume":"34","author":"Bardazzi","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Witte, M., Zillikens, D., and Schmidt, E. (2018). Diagnosis of Autoimmune Blistering Diseases. Front. Med., 5.","DOI":"10.3389\/fmed.2018.00296"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Saschenbrecker, S., Karl, I., Komorowski, L., Probst, C., D\u00e4hnrich, C., Fechner, K., St\u00f6cker, W., and Schlumberger, W. (2019). Serological Diagnosis of Autoimmune Bullous Skin Diseases. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01974"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.2340\/00015555-2737","article-title":"Quality of Life in Greek Patients with Autoimmune Bullous Diseases Assessed with ABQOL and TABQOL Indexes","volume":"97","author":"Patsatsi","year":"2017","journal-title":"Acta Derm. Venereol."},{"key":"ref_6","first-page":"713","article-title":"S2k guideline for the diagnosis of pemphigus vulgaris\/foliaceus and bullous pemphigoid","volume":"13","author":"Schmidt","year":"2015","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jaad.2020.08.028","article-title":"Network meta-analysis-based comparison of first-line steroid-sparing adjuvants in the treatment of pemphigus vulgaris and pemphigus foliaceus","volume":"85","author":"Lee","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_8","first-page":"176","article-title":"Dapsone\u2014Mechanism of action, safety of use and the role in the treatment of bullous pemphigoid according to current recommendations","volume":"103","author":"Szepietowski","year":"2016","journal-title":"Derm. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1007\/s00210-022-02297-1","article-title":"A comprehensive insight into the anti-inflammatory properties of dapsone","volume":"395","author":"Khalilzadeh","year":"2022","journal-title":"Arch. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/bjd.15963","article-title":"Dapsone: A forgotten and underestimated treatment option for bullous pemphigoid?","volume":"177","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00403-013-1409-7","article-title":"Dapsone in dermatology and beyond","volume":"306","author":"Wozel","year":"2014","journal-title":"Arch. Dermatol. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"183","DOI":"10.5114\/ceji.2021.107028","article-title":"Conceptualization and Validation of an Innovative Direct Immunofluorescence Technique Utilizing Fluorescein Conjugate against IgG + IgG4 for Routinely Diagnosing Autoimmune Bullous Dermatoses","volume":"46","author":"Kaczmarek","year":"2021","journal-title":"Cent. Eur. J. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(08)60073-2","article-title":"Glucose-6-phosphate dehydrogenase deficiency","volume":"371","author":"Cappellini","year":"2008","journal-title":"Lancet"},{"key":"ref_14","first-page":"170","article-title":"Czy nale\u017cy ocenia\u0107 aktywno\u015b\u0107 dehydrogenazy glukozo-6-fosforanowej (G6PD) przed podaniem Dapsonu u ka\u017cdego pacjenta, czy tylko w grupach ryzyka w populacji polskiej?\/Should the activity of glucose-6-phosphate dehydrogenase (G6PD) be assessed before administering Dapsone in every patient or only in risk groups in Poland?","volume":"8","author":"Szepietowski","year":"2022","journal-title":"Forum Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jaad.2008.01.012","article-title":"Consensus Statement on Definitions of Disease, End Points, and Therapeutic Response for Pemphigus","volume":"58","author":"Murrell","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Spa\u0142ek, M.M., Ja\u0142owska, M., Bowszyc-Dmochowska, M., and Dmochowski, M. (2024). Rituximab in the Management of Autoimmune Bullous Diseases: A Treatment-Resistant Case Series from a Single Central European Referral Center. Medicina, 60.","DOI":"10.3390\/medicina60020270"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Spa\u0142ek, M.M., Bowszyc-Dmochowska, M., and Dmochowski, M. (2023). Intravenous Immunoglobulin for Autoimmune Bullous Diseases: A Case Series from a Central European Referral Center. Medicina, 59.","DOI":"10.3390\/medicina59071265"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1365-2133.2005.06559.x","article-title":"Dapsone suppresses human neutrophil superoxide production and elastase release in a calcium-dependent manner","volume":"152","author":"Suda","year":"2005","journal-title":"Br. J. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/1523-1747.ep12471811","article-title":"Inhibition of neutrophil adherence to antibody by dapsone: A possible therapeutic mechanism of dapsone in the treatment of IgA dermatoses","volume":"100","author":"Kadunce","year":"1993","journal-title":"J. Investig. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1159\/000233335","article-title":"Granulocyte-mediated release of histamine from mast cells: Effect of myeloperoxidase and its inhibition by antiinflammatory sulfone compounds","volume":"70","author":"Stendahl","year":"1983","journal-title":"Int. Arch. Allergy Appl. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1046\/j.1365-2249.2001.01503.x","article-title":"The IL-8 release from cultured human keratinocytes, mediated by antibodies to bullous pemphigoid autoantigen 180, is inhibited by dapsone","volume":"124","author":"Schmidt","year":"2001","journal-title":"Clin. Exp. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/j.1365-2230.2008.02864.x","article-title":"A possible inhibitory action of diaminodiphenyl sulfone on tumour necrosis factor-alpha production from activated mononuclear cells on cutaneous lupus erythematosus","volume":"33","author":"Abe","year":"2008","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3109\/08916934.2012.697593","article-title":"Cytokine networks in Pemphigus vulgaris: An integrated viewpoint","volume":"45","author":"Giordano","year":"2012","journal-title":"Autoimmunity"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/07853890.2020.1742367","article-title":"Factors associated with the activity and severity of bullous pemphigoid: A review","volume":"52","author":"Liu","year":"2020","journal-title":"Ann. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1001\/archderm.1989.01670190059006","article-title":"Mediators of inflammation in blister fluids from patients with pemphigus vulgaris and bullous pemphigoid","volume":"125","author":"Grando","year":"1989","journal-title":"Arch. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/0006-2952(83)90568-3","article-title":"Inhibition of the release of prostaglandins, leukotrienes and lysosomal acid hydrolases from macrophages by selective inhibitors of lecithin biosynthesis","volume":"32","author":"Bonney","year":"1983","journal-title":"Biochem. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/0091-6749(91)90393-3","article-title":"The effect of dapsone in steroid-dependent asthma","volume":"87","author":"Berlow","year":"1991","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1016\/j.jid.2021.04.009","article-title":"Dapsone Suppresses Disease in Preclinical Murine Models of Pemphigoid Diseases","volume":"141","author":"Murthy","year":"2021","journal-title":"J. Investig. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1001\/archderm.1976.01630310024005","article-title":"Pemphigus: A 20-year review of 107 patients treated with corticosteroids","volume":"112","author":"Rosenberg","year":"1976","journal-title":"Arch. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/j.1365-2133.1976.tb05168.x","article-title":"Pemphigus controlled by dapsone","volume":"94","author":"Piamphongsant","year":"1976","journal-title":"Br. J. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000250907","article-title":"Dapsone in the treatment of pemphigus vulgaris","volume":"156","author":"Haim","year":"1978","journal-title":"Dermatologica"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/archderm.144.1.25","article-title":"Multicenter Randomized, Double-blind, Placebo-Controlled, Clinical Trial of Dapsone as a Glucocorticoid-Sparing Agent in Maintenance-Phase Pemphigus Vulgaris","volume":"144","author":"Werth","year":"2008","journal-title":"Arch. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jaad.2013.05.016","article-title":"Assessment of the rate of long-term complete remission off therapy in patients with pemphigus treated with different regimens including medium- and high-dose corticosteroids","volume":"69","author":"Almugairen","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1159\/000448028","article-title":"Efficacy of Dapsone in the Treatment of Pemphigus Vulgaris: A Single-Center Case Study","volume":"232","author":"Baum","year":"2016","journal-title":"Dermatology"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Mocanu, M., Procopciuc, D., Gheuc\u0103-Solov\u0103stru, D.-F., Popescu, I.A., Olinici, D.T., P\u0103tra\u0219cu, A.I., V\u00e2\u021b\u0103, D., and Gheuc\u0103-Solov\u0103stru, L. (2024). An Overview of Methotrexate Indications in Skin Diseases. Medicina, 60.","DOI":"10.3390\/medicina60071024"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"7525","DOI":"10.1038\/s41598-022-11387-2","article-title":"A randomised clinical trial to assess the adjuvant potential of methotrexate to corticosteroids in mucosal or limited mucocutaneous pemphigus vulgaris","volume":"12","author":"Jain","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1365-2230.2008.02881.x","article-title":"A clinical study of patients with pemphigus vulgaris and pemphigus foliaceous: An 11-year retrospective study (1996\u20132006)","volume":"33","author":"Ishii","year":"2008","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2165\/11310740-000000000-00000","article-title":"Efficacy of dapsone in the treatment of pemphigus and pemphigoid: Analysis of current data","volume":"10","author":"Gurcan","year":"2009","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/jdv.18220","article-title":"Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)","volume":"36","author":"Borradori","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1111\/jdv.17395","article-title":"European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology\u2014Part II","volume":"35","author":"Schmidt","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_41","first-page":"227","article-title":"Results of a survey of German dermatologists on the therapeutic approaches to pemphigus and bullous pemphigoid","volume":"7","author":"Hofmann","year":"2009","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_42","first-page":"335","article-title":"Bullous pemphigoid in Iranian patients: A descriptive study on 122 cases","volume":"50","author":"Esmaili","year":"2012","journal-title":"Acta Med. Iran"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2340\/00015555-1925","article-title":"A retrospective consecutive case-series study on the effect of systemic treatment, length of admission time and co-morbidities in 98 bullous pemphigoid patients admitted to a tertiary centre","volume":"95","author":"Kibsgaard","year":"2015","journal-title":"Acta Derm. Venereol."},{"key":"ref_44","first-page":"19","article-title":"Dapsone for the treatment of bullous pemphigoid","volume":"1","author":"Piamphongsant","year":"1983","journal-title":"Asian Pac. J. Allergy Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-2133.1989.tb07769.x","article-title":"Dapsone as the first line treatment for bullous pemphigoid","volume":"120","author":"Venning","year":"1989","journal-title":"Br. J. Dermatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1001\/archderm.1977.01640050070009","article-title":"Bullous pemphigoid responding to sulfapyridine and the sulfones","volume":"113","author":"Person","year":"1977","journal-title":"Arch. Dermatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0190-9622(96)80085-5","article-title":"Treatment of bullous pemphigoid with dapsone: Retrospective study of thirty-six case","volume":"34","author":"Bouscarat","year":"1996","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.aller.2010.12.009","article-title":"Efficacy and safety of azathioprine and dapsone as an adjuvant in the treatment of bullous pemphigoid","volume":"40","year":"2012","journal-title":"Allergol. Immunopathol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/bjd.15649","article-title":"An open, multicentre, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone","volume":"177","author":"Sticherling","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1016\/j.oooo.2012.01.030","article-title":"Treatment of mucous membrane pemphigoid with the combination of mycophenolate mofetil, dapsone, and prednisolone: A case series","volume":"114","author":"Staines","year":"2012","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/ICO.0000000000003071","article-title":"A 10-Year Review of the Management of Ocular Mucous Membrane Pemphigoid: A Private Practice Experience","volume":"42","author":"Johnson","year":"2023","journal-title":"Cornea"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1080\/01480545.2019.1679829","article-title":"Dapsone-induced hepatic complications: It\u2019s time to think beyond methemoglobinemia","volume":"44","author":"Ezhilarasan","year":"2021","journal-title":"Drug Chem. Toxicol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2174\/1574886313666180731123232","article-title":"Dapsone Hypersensitivity Syndrome (DHS): A Detrimental Effect of Dapsone? A Case Report","volume":"14","author":"Shukkoor","year":"2019","journal-title":"Curr. Drug. Saf."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1007\/s12098-020-03226-x","article-title":"Dapsone Induced Agranulocytosis and Hemolytic Anemia in Immune Thrombocytopenic Purpura","volume":"87","author":"Bartakke","year":"2020","journal-title":"Indian J. Pediatr."},{"key":"ref_55","first-page":"e14026","article-title":"Dapsone Hypersensitivity Syndrome with Leukemoid Reaction and Severe Thrombocytosis","volume":"13","author":"Pahadiya","year":"2021","journal-title":"Cureus"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1365-2133.1993.tb00476.x","article-title":"Dapsone: Modes of action, toxicity and possible strategies for increasing patient tolerance","volume":"129","author":"Coleman","year":"1993","journal-title":"Br. J. Dermatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0300-483X(01)00360-2","article-title":"Dapsone-mediated agranulocytosis: Risks, possible mechanisms and prevention","volume":"162","author":"Coleman","year":"2001","journal-title":"Toxicology"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"286","DOI":"10.7326\/0003-4819-110-4-286","article-title":"Diagnosis of sulfonamide hypersensitivity reactions by in-vitro \u201crechallenge\u201d with hydroxylamine metabolites","volume":"110","author":"Rieder","year":"1989","journal-title":"Ann. Intern. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamadermatol.2018.5360","article-title":"Evaluation of Prospective HLA-B*13:01 Screening to Prevent Dapsone Hypersensitivity Syndrome in Patients with Leprosy","volume":"155","author":"Liu","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1056\/NEJMoa1213096","article-title":"HLA-B*13:01 and the dapsone hypersensitivity syndrome","volume":"369","author":"Zhang","year":"2013","journal-title":"N. Engl. J. Med."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/8\/1324\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:37:11Z","timestamp":1760110631000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/8\/1324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,15]]},"references-count":60,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["medicina60081324"],"URL":"https:\/\/doi.org\/10.3390\/medicina60081324","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,15]]}}}